Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona histologicznie (badaniem tkanki) diagnoza chłoniaka strefy przejściowej
- •Choroba w stadium I-IV
- •Pacjent nigdy wcześniej nie otrzymywał leczenia systemowego (ogólnoustrojowego)
- •Widoczne powiększone węzły chłonne lub nowotwór widoczny w badaniach obrazowych (PET/CT, CT lub MRI)
- •Zdolność i chęć do podpisania zgody na uczestnictwo w badaniu
- •Możliwość przestrzegania wymagań badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Miami
Miami, United States
Trial contact
Izidore Lossos, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.